{"id":1913,"date":"2015-02-12T18:03:22","date_gmt":"2015-02-12T16:03:22","guid":{"rendered":"https:\/\/colox.ch\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/"},"modified":"2018-03-09T14:12:45","modified_gmt":"2018-03-09T13:12:45","slug":"novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer","status":"publish","type":"post","link":"https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/","title":{"rendered":"Novigenix acquires blood-based molecular diagnostics test Colox\u00ae and prepares its further commercial rollout in Switzerland and Europe to improve the early detection of colorectal cancer"},"content":{"rendered":"<p>LAUSANNE, Switzerland, February 12, 2015 \u2013 Molecular diagnostics company Novigenix<br \/>\nSA announced today it acquired <a href=\"https:\/\/colox.ch\/colox\/\">Colox<\/a>\u00ae, a new molecular blood test for the detection<br \/>\nof colorectal cancer and pre-cancerous lesions (adenomatous polyps). Colox has<br \/>\nbeen approved for sale in Europe, and has been launched commercially in<br \/>\nSwitzerland. Novigenix aims to increase the availability of Colox in Switzerland and<br \/>\nEurope through partnerships.<br \/>\nBrian Hashemi, Executive Chairman of Novigenix SA, said: \u201cOur vision is to support<br \/>\nphysicians and the healthcare community in significantly reducing cancer mortality<br \/>\nthrough the early diagnosis and intervention of colorectal cancer. We are committed<br \/>\nto making Colox available to physicians and patients across Switzerland, followed by<br \/>\nexpansion in other European countries. Colorectal cancer is today the third most lethal<br \/>\ncancer, but can be largely prevented if detected early by an accurate, reliable, and<br \/>\nconvenient test such as Colox.\u201d<br \/>\nColox has been tested in a <a href=\"http:\/\/clincancerres.aacrjournals.org\/content\/early\/2016\/04\/28\/1078-0432.CCR-15-2057\">multi-center clinical study <\/a>in Switzerland led by Professor<br \/>\nGian Dorta, MD, in Internal Medicine Department, at the Service of Gastroenterology<br \/>\nand Hepatology, Centre Hospitalier Universitaire Vaudois, Lausanne (CHUV). \u201cColox<br \/>\naccurately and reliably detects both adenomatous polyps and early stages of<br \/>\ncolorectal cancer with a convenient blood test that can be ordered as part of a<br \/>\nroutine medical checkup. As a result Colox has the potential to dramatically increase<br \/>\nscreening compliance and reduce the mortality rate from this deadly disease,\u201d said<br \/>\nProfessor Dorta.<br \/>\nColox, originally developed by Diagnoplex SA, represents a new generation of cancer<br \/>\ndiagnostic tests based on the response of the organism against the tumor. Peripheral<br \/>\nBlood Mononuclear Cells (PBMCs) are particularly responsive to growing<br \/>\nadenomatous polyps and colorectal carcinomas. Determining the expression of 29<br \/>\ngenes in PBMCs provides a telltale sign of the early stages of colorectal cancer. Gene<br \/>\nexpression data are interpreted by Novigenix\u2019s proprietary algorithm which generates<br \/>\nthe Colox test report. This algorithm is based on classifier combinations derived from<br \/>\nmathematical analytical methods that underpin the reliability of the test.<\/p>\n<p><strong>About Novigenix SA:<\/strong><br \/>\nNovigenix SA is an innovative Swiss molecular diagnostics company focused on the<br \/>\ncommercialization of new screening and diagnostics tools for early detection of<br \/>\ncancer. Novigenix\u2019s products rely on a new generation of predictive molecular<br \/>\nsignatures and state-of-the-art mathematical analytical models to provide new<br \/>\nsolutions for the early diagnosis of cancer. For more information please visit<br \/>\n<a href=\"https:\/\/colox.ch\">www.novigenix.com<\/a><\/p>\n<p><strong>About Colox\u00ae:<\/strong><br \/>\nColox\u00ae is a proven molecular blood test that has been designed to support the<br \/>\nhealthcare community in significantly reducing mortality from colorectal cancer<br \/>\nthrough early diagnosis and intervention. This convenient blood test can be ordered<br \/>\nby a physician during a routine medical checkup to accurately and reliably detect<br \/>\nboth adenomatous polyps and early stages of colorectal cancer. Colox is available<br \/>\nas a Laboratory Developed Test and is highly suited to standard medical laboratory<br \/>\nworkflow. Colox is also available as a CE registered kit.<br \/>\nNOTE: Colox\u00ae has been approved for sale in Europe. It is not yet approved for use in<br \/>\nthe United States.<\/p>\n<p><em>Contact:<\/em><br \/>\nNovigenix SA<br \/>\nChristian Jauch, Director of Finance<br \/>\nChristian.Jauch@colox.ch<br \/>\nTel: +41 21 552 07 30<br \/>\nCell: +41 79 768 38 20<\/p>\n","protected":false},"excerpt":{"rendered":"<p>LAUSANNE, Switzerland, February 12, 2015 \u2013 Molecular diagnostics company Novigenix SA announced today it acquired Colox\u00ae, a new molecular blood test for the detection of colorectal cancer and pre-cancerous lesions (adenomatous polyps). Colox has been approved for sale in Europe, and has been launched commercially in Switzerland. Novigenix aims to increase the availability of Colox [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37],"tags":[],"class_list":["post-1913","post","type-post","status-publish","format-standard","hentry","category-communique-de-presse-de"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novigenix acquires blood-based molecular diagnostics test Colox\u00ae and prepares its further commercial rollout in Switzerland and Europe to improve the early detection of colorectal cancer - Colox<\/title>\n<meta name=\"description\" content=\"Molecular diagnostics company Novigenix SA announced today it acquired Colox\u00ae, a new molecular blood test for the detection of colorectal cancer and pre-cancerous lesions (adenomatous polyps). Colox has been approved for sale in Europe, and has been launched commercially in Switzerland.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novigenix acquires blood-based molecular diagnostics test Colox\u00ae and prepares its further commercial rollout in Switzerland and Europe to improve the early detection of colorectal cancer - Colox\" \/>\n<meta property=\"og:description\" content=\"Molecular diagnostics company Novigenix SA announced today it acquired Colox\u00ae, a new molecular blood test for the detection of colorectal cancer and pre-cancerous lesions (adenomatous polyps). Colox has been approved for sale in Europe, and has been launched commercially in Switzerland.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Colox\" \/>\n<meta property=\"article:published_time\" content=\"2015-02-12T16:03:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-03-09T13:12:45+00:00\" \/>\n<meta name=\"author\" content=\"Sebastien\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sebastien\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/\"},\"author\":{\"name\":\"Sebastien\",\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/person\/8626a29b6ce992c1956ab2bea651cc41\"},\"headline\":\"Novigenix acquires blood-based molecular diagnostics test Colox\u00ae and prepares its further commercial rollout in Switzerland and Europe to improve the early detection of colorectal cancer\",\"datePublished\":\"2015-02-12T16:03:22+00:00\",\"dateModified\":\"2018-03-09T13:12:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/\"},\"wordCount\":523,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/colox.ch\/de\/#organization\"},\"articleSection\":[\"Communiqu\u00e9 de presse\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/\",\"url\":\"https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/\",\"name\":\"Novigenix acquires blood-based molecular diagnostics test Colox\u00ae and prepares its further commercial rollout in Switzerland and Europe to improve the early detection of colorectal cancer - Colox\",\"isPartOf\":{\"@id\":\"https:\/\/colox.ch\/de\/#website\"},\"datePublished\":\"2015-02-12T16:03:22+00:00\",\"dateModified\":\"2018-03-09T13:12:45+00:00\",\"description\":\"Molecular diagnostics company Novigenix SA announced today it acquired Colox\u00ae, a new molecular blood test for the detection of colorectal cancer and pre-cancerous lesions (adenomatous polyps). Colox has been approved for sale in Europe, and has been launched commercially in Switzerland.\",\"breadcrumb\":{\"@id\":\"https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/colox.ch\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novigenix acquires blood-based molecular diagnostics test Colox\u00ae and prepares its further commercial rollout in Switzerland and Europe to improve the early detection of colorectal cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/colox.ch\/de\/#website\",\"url\":\"https:\/\/colox.ch\/de\/\",\"name\":\"Colox\",\"description\":\"The new generation blood test\",\"publisher\":{\"@id\":\"https:\/\/colox.ch\/de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/colox.ch\/de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/colox.ch\/de\/#organization\",\"name\":\"Novigenix SA\",\"url\":\"https:\/\/colox.ch\/de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png\",\"contentUrl\":\"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png\",\"width\":700,\"height\":297,\"caption\":\"Novigenix SA\"},\"image\":{\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/person\/8626a29b6ce992c1956ab2bea651cc41\",\"name\":\"Sebastien\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/76fcf0fca23b7dcc8d06f492337248c6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/76fcf0fca23b7dcc8d06f492337248c6?s=96&d=mm&r=g\",\"caption\":\"Sebastien\"},\"url\":\"https:\/\/colox.ch\/de\/author\/sebastien\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novigenix acquires blood-based molecular diagnostics test Colox\u00ae and prepares its further commercial rollout in Switzerland and Europe to improve the early detection of colorectal cancer - Colox","description":"Molecular diagnostics company Novigenix SA announced today it acquired Colox\u00ae, a new molecular blood test for the detection of colorectal cancer and pre-cancerous lesions (adenomatous polyps). Colox has been approved for sale in Europe, and has been launched commercially in Switzerland.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/","og_locale":"de_DE","og_type":"article","og_title":"Novigenix acquires blood-based molecular diagnostics test Colox\u00ae and prepares its further commercial rollout in Switzerland and Europe to improve the early detection of colorectal cancer - Colox","og_description":"Molecular diagnostics company Novigenix SA announced today it acquired Colox\u00ae, a new molecular blood test for the detection of colorectal cancer and pre-cancerous lesions (adenomatous polyps). Colox has been approved for sale in Europe, and has been launched commercially in Switzerland.","og_url":"https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/","og_site_name":"Colox","article_published_time":"2015-02-12T16:03:22+00:00","article_modified_time":"2018-03-09T13:12:45+00:00","author":"Sebastien","twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"Sebastien","Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/#article","isPartOf":{"@id":"https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/"},"author":{"name":"Sebastien","@id":"https:\/\/colox.ch\/de\/#\/schema\/person\/8626a29b6ce992c1956ab2bea651cc41"},"headline":"Novigenix acquires blood-based molecular diagnostics test Colox\u00ae and prepares its further commercial rollout in Switzerland and Europe to improve the early detection of colorectal cancer","datePublished":"2015-02-12T16:03:22+00:00","dateModified":"2018-03-09T13:12:45+00:00","mainEntityOfPage":{"@id":"https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/"},"wordCount":523,"commentCount":0,"publisher":{"@id":"https:\/\/colox.ch\/de\/#organization"},"articleSection":["Communiqu\u00e9 de presse"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/","url":"https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/","name":"Novigenix acquires blood-based molecular diagnostics test Colox\u00ae and prepares its further commercial rollout in Switzerland and Europe to improve the early detection of colorectal cancer - Colox","isPartOf":{"@id":"https:\/\/colox.ch\/de\/#website"},"datePublished":"2015-02-12T16:03:22+00:00","dateModified":"2018-03-09T13:12:45+00:00","description":"Molecular diagnostics company Novigenix SA announced today it acquired Colox\u00ae, a new molecular blood test for the detection of colorectal cancer and pre-cancerous lesions (adenomatous polyps). Colox has been approved for sale in Europe, and has been launched commercially in Switzerland.","breadcrumb":{"@id":"https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/colox.ch\/de\/novigenix-acquires-blood-based-molecular-diagnostics-test-colox-and-prepares-its-further-commercial-rollout-in-switzerland-and-europe-to-improve-the-early-detection-of-colorectal-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/colox.ch\/"},{"@type":"ListItem","position":2,"name":"Novigenix acquires blood-based molecular diagnostics test Colox\u00ae and prepares its further commercial rollout in Switzerland and Europe to improve the early detection of colorectal cancer"}]},{"@type":"WebSite","@id":"https:\/\/colox.ch\/de\/#website","url":"https:\/\/colox.ch\/de\/","name":"Colox","description":"The new generation blood test","publisher":{"@id":"https:\/\/colox.ch\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/colox.ch\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/colox.ch\/de\/#organization","name":"Novigenix SA","url":"https:\/\/colox.ch\/de\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/","url":"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png","contentUrl":"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png","width":700,"height":297,"caption":"Novigenix SA"},"image":{"@id":"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/colox.ch\/de\/#\/schema\/person\/8626a29b6ce992c1956ab2bea651cc41","name":"Sebastien","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/colox.ch\/de\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/76fcf0fca23b7dcc8d06f492337248c6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/76fcf0fca23b7dcc8d06f492337248c6?s=96&d=mm&r=g","caption":"Sebastien"},"url":"https:\/\/colox.ch\/de\/author\/sebastien\/"}]}},"_links":{"self":[{"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/posts\/1913"}],"collection":[{"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/comments?post=1913"}],"version-history":[{"count":0,"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/posts\/1913\/revisions"}],"wp:attachment":[{"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/media?parent=1913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/categories?post=1913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/colox.ch\/de\/wp-json\/wp\/v2\/tags?post=1913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}